162 related articles for article (PubMed ID: 36326360)
1. Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group).
Erol C; Sakin A; Başoğlu T; Özden E; Çabuk D; Doğan M; Öksüzoğlu B; Yıldırım HÇ; Öner İ; Eryılmaz MK; Dülgar Ö; Aydın D; Doğan N; Özen M; Hacıbekiroğlu İ; Özdemir N; Gürler F; Paksoy N; Karabulut S; Aksoy A; Hızal M; Kahraman S; Şen E; Paydaş S; Çılbır E; Fırat F; Akdeniz N; Özçelik M; Oyman A; Baytemür NK; Acar R; Almuradova E; Karabulut B; Şakalar T; Arak H; Değerli E; Türker S; Alan Ö; Er Ö; Taşçı EŞ; Demir N; Çavdar E; Turhal S; Dede DŞ; Akıncı MB; Yalçın B; Yumuk F; Yalçın Ş; Şendur MAN
Turk J Med Sci; 2022 Aug; 52(4):1022-1032. PubMed ID: 36326360
[TBL] [Abstract][Full Text] [Related]
2. Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study.
Başoğlu T; Sakin A; Erol C; Özden E; Çabuk D; Çılbır E; Tataroğlu Özyükseler D; Ayhan M; Şendur MA; Dogan M; Öksüzoğlu B; Eryılmaz MK; Er Ö; Taşçı EŞ; Özyurt N; Dülgar Ö; Özen M; Hacıbekiroğlu İ; Öner İ; Bekmez ET; Çağrı Yıldırım H; Yalçın Ş; Paydaş S; Yekedüz E; Aksoy A; Özçelik M; Oyman A; Almuradova E; Karabulut B; Demir N; Dinçer M; Özdemir N; Erdem D; Ak N; İnal A; Salim DK; Deniz Gİ; Şakalar T; Gülmez A; Kaçan T; Özdemir Ö; Alan Ö; Ünal Ç; Karakaş Y; Turhal S; Yumuk PF
J Chemother; 2023 Apr; 35(2):142-149. PubMed ID: 35579894
[TBL] [Abstract][Full Text] [Related]
3. Results of the observational prospective RealFLOT study.
Giommoni E; Lavacchi D; Tirino G; Fornaro L; Iachetta F; Pozzo C; Satolli MA; Spallanzani A; Puzzoni M; Stragliotto S; Sisani M; Formica V; Giovanardi F; Strippoli A; Prisciandaro M; Di Donato S; Pompella L; Pecora I; Romagnani A; Fancelli S; Brugia M; Pillozzi S; De Vita F; Antonuzzo L
BMC Cancer; 2021 Oct; 21(1):1086. PubMed ID: 34625033
[TBL] [Abstract][Full Text] [Related]
4. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
[TBL] [Abstract][Full Text] [Related]
5. Perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) for esophagogastric adenocarcinoma: ten years real-life experience from a surgical perspective.
Sisic L; Crnovrsanin N; Nienhueser H; Jung JO; Schiefer S; Haag GM; Bruckner T; Schneider M; Müller-Stich BP; Büchler MW; Schmidt T
Langenbecks Arch Surg; 2023 Feb; 408(1):81. PubMed ID: 36763220
[TBL] [Abstract][Full Text] [Related]
6. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
Lorenzen S; Biederstädt A; Ronellenfitsch U; Reißfelder C; Mönig S; Wenz F; Pauligk C; Walker M; Al-Batran SE; Haller B; Hofheinz RD
BMC Cancer; 2020 Sep; 20(1):886. PubMed ID: 32933498
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of the FLOT regimen in the Polish population - an analysis of the prospective trial.
Marcisz-Grzanka K; Winiarek M; Pałucki J; Wieszczy P; Olesiński T; Jóźwiak M; Samsel R; Sułkowska U; Kolasińska-Ćwikła A; Wyrwicz LS
Neoplasma; 2022 Dec; 69(6):1445-1450. PubMed ID: 36353936
[TBL] [Abstract][Full Text] [Related]
8. Perioperative therapy with FLOT4 significantly increases survival in patients with gastroesophageal and gastric cancer in a large real-world cohort.
Möhring C; Mańczak A; Timotheou A; Sadeghlar F; Zhou T; Mahn R; Monin MB; Toma M; Feldmann G; Brossart P; Köksal M; Sarria GR; Sommer N; Lingohr P; Jafari A; Kalff JC; Strassburg CP; Gonzalez-Carmona MA
Int J Cancer; 2023 Aug; 153(3):609-622. PubMed ID: 36919950
[TBL] [Abstract][Full Text] [Related]
9. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
[TBL] [Abstract][Full Text] [Related]
10. Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimens.
Moore JL; Kumar S; Santaolalla A; Patel PH; Kapiris M; Van Hemelrijck M; Maisey N; Hill M; Lagergren J; Gossage JA; Kelly M; Chaudry A; Allum WH; Baker CR; Cunningham D; Davies AR;
Eur J Cancer; 2022 Mar; 163():180-188. PubMed ID: 35085931
[TBL] [Abstract][Full Text] [Related]
11. Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol.
Huemer F; Hecht S; Scharinger B; Schlintl V; Rinnerthaler G; Schlick K; Heregger R; Melchardt T; Wimmer A; Mühlbacher I; Koch OO; Neureiter D; Klieser E; Seyedinia S; Beheshti M; Greil R; Weiss L
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3051-3064. PubMed ID: 35864270
[TBL] [Abstract][Full Text] [Related]
12. Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis.
Grizzi G; Petrelli F; Di Bartolomeo M; Viti M; Texeira Moraes M; Luciani A; Passalacqua R; Ghidini M; Tomasello G; Baiocchi GL; Celotti A
Gastric Cancer; 2022 Sep; 25(5):982-987. PubMed ID: 35704113
[TBL] [Abstract][Full Text] [Related]
13. Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study.
Nappo F; Fornaro L; Pompella L; Catanese S; Lavacchi D; Spallanzani A; Cappetta A; Puzzoni M; Murgioni S; Barsotti G; Tirino G; Pellino A; Vivaldi C; Strippoli A; Aprile G; Di Donato S; Mazza E; Prisciandaro M; Antonuzzo L; Zagonel V; Cascinu S; De Vita F; Lonardi S
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6601-6611. PubMed ID: 36795195
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group.
Hofheinz RD; Hegewisch-Becker S; Kunzmann V; Thuss-Patience P; Fuchs M; Homann N; Graeven U; Schulte N; Merx K; Pohl M; Held S; Keller R; Tannapfel A; Al-Batran SE
Int J Cancer; 2021 Sep; 149(6):1322-1331. PubMed ID: 34019698
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer.
Lorenzen S; Pauligk C; Homann N; Schmalenberg H; Jäger E; Al-Batran SE
Br J Cancer; 2013 Feb; 108(3):519-26. PubMed ID: 23322206
[TBL] [Abstract][Full Text] [Related]
16. CROSS or FLOT in Distal Esophageal and Gastroesophageal Cancer.
Karadag I; Karakaya S; Ates O; Cakmak Oksuzoglu OB
J Coll Physicians Surg Pak; 2021 Mar; 31(3):326-329. PubMed ID: 33775025
[TBL] [Abstract][Full Text] [Related]
17. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
[TBL] [Abstract][Full Text] [Related]
18. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
19. Impact of Signet-Ring Cell Histology in the Management of Patients with Non-Metastatic Gastric Cancer: Results from a Retrospective Multicenter Analysis Comparing FLOT Perioperative Chemotherapy vs. Surgery Followed by Adjuvant Chemotherapy.
Giampieri R; Baleani MG; Bittoni A; Rastelli F; Catalano V; Del Prete M; Chiorrini S; Pinterpe G; Graziano F; Giorgi FC; Bisonni R; Silva R; Alessandroni P; Mencarini L; Berardi R
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444451
[TBL] [Abstract][Full Text] [Related]
20. Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy.
Tian S; Jiang R; Madden NA; Ferris MJ; Buchwald ZS; Xu KM; Cardona K; Maithel SK; McDonald MW; Lin JY; Curran WJ; El-Rayes BF; Behera M; Patel PR
Cancer; 2020 Jan; 126(1):37-45. PubMed ID: 31532544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
